Trump unveils drug pricing plan

May 14, 2018

President Trump unveiled a long-awaited plan for lowering drug prices on Friday.

The two issues that were most opposed by the pharma industry — allowing Medicare to directly negotiate drug pricing and allowing Americans to import prescription drugs — were largely avoided.

A list of possible solutions that will be explored by Trump included:

• Allowing Medicare drug plans to pay different prices for the same drug, depending on the disease being treated
• Exploring “value-based purchasing” in federal programs, where a drugmaker may have to refund money if a treatment does not work as expected
• Making generic drugs free for some low-income older people on Medicare
• Pushing other countries to raise drug prices in order to lower prices in the U.S.
• Requiring drugmakers to mention the price of drugs in drug commercials 
• Ending contracts between pharmacies and pharmacy benefit managers that prohibit pharmacists from informing patients when a drug would be cheaper if they paid in cash, rather than using insurance
• Cracking down on patent extension tactics employed by branded pharma 

The administration also released a 39-page document  describing a variety of proposals it is either considering or studying as part of its lower drug costs efforts.

The speech was well-received by the Association for Accessible Medicines, who applauded  the President’s emphasis on the role competition plays in decreasing drug prices.

The Pharmaceutical Research and Manufacturers of America (PhRMA) had a more mixed reaction, mostly voicing concern surrounding proposed changes to Medicare Part D.

Read the NY Times coverage


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments